Bain Capital Life Sciences

Bain Capital Life Sciences was founded in 2016 and builds on Bain Capital's four decades of healthcare and life sciences investing across private equity, public equity, credit, venture capital and real estate, according to its website. The team invests in biopharmaceutical, medical device, diagnostic and life science tool companies across the globe, with a focus on companies that drive medical innovation to improve the lives of patients with unmet medical needs.^[1]

Bain Capital Life Sciences targets four types of investment opportunities, according to its approach page: Inflection Capital, engaging with companies at critical stages of development; Growth Capital, supporting companies to accelerate commercialization and expand into new geographies; Fallen Angels, partnering with companies at a crossroads to create value; and Transformation at Scale, creating, building and restructuring companies for their next inflection point.^[2]

Bain Capital Life Sciences is headquartered in Boston, according to its about page, and also lists team members in Melbourne, New York and Shanghai on its people page.^[3]

Bain Capital led a $300 million financing commitment for a new independent biopharmaceutical company formed with Bristol Myers Squibb, announced July 28, 2025, to develop immunology therapies for autoimmune diseases. The new company launched with five immunology assets in-licensed from BMS, including afimetoran, an oral TLR7/8 inhibitor in Phase 2 trials for systemic lupus erythematosus, and BMS-986322, an oral TYK2 inhibitor that had established proof-of-concept in a Phase 2 plaque psoriasis trial, according to the companies' press release.^[4]

Bristol Myers Squibb retained a nearly 20 percent equity stake in the new company and will be entitled to royalties and milestones tied to the success of each licensed asset, according to the joint press release. Robert Plenge, Executive Vice President and Chief Research Officer at BMS, joined the new company's board of directors as part of the agreement.^[4]

Bain Capital Life Sciences' people page lists Nicholas Downing, Andrew Hack, Adam M. Koppel, Ricky Lijing Sun and Amir Zamani as Partners based in Boston. Adam Koppel discussed private equity's role in biotech in a January 8, 2026 BioCentury interview linked from the firm's own news page.^[3],[5]

Bain Capital Life Sciences' team also includes Managing Directors Matthew Calistri, Will Cozean, Lei Meng, John Trzupek and Renjie Wang, and Principals Jonah Cashdan, Leonard Feiner, Drew Field and Evan Greif, according to the firm's people page.^[3]

Bain Capital Life Sciences' news page lists Beeline Medicines' debut, announced April 15, 2026, as a press release describing a new company delivering precision therapies for people living with autoimmune and inflammatory diseases, according to the firm's own news listing. The sources opened for this profile give only the headline for that announcement and do not describe Beeline's funding amount or founding team.^[5]

Bain Capital's purchase of a 340-year-old pharmaceutical company to help fast-track drug development in Japan was covered by the Financial Times in a story dated February 7, 2025 and linked from Bain Capital Life Sciences' own news page. The sources opened for this profile give only the headline and publication date for that Financial Times story and do not state the acquisition price or the company's name.^[5]